Skip to content

Clinical trials

Diabetes Mellitus trials in the Netherlands

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus Country / region: Netherlands Clear all

188 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20013
20024
20037
20047
20059
200613
200711
20086
200913
201010
20119
201210
201311
201412
20158
20163
20176
20186
20193
20203
20215
20228
20236
20244
20253
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed143
Unknown status18
Terminated11
Recruiting9
Enrolling by invitation3
Active, not recruiting2
Suspended1
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S39
Radboud University Medical Center14
University Medical Center Groningen12
Maastricht University Medical Center9
AstraZeneca8
Takeda8
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)6
Amsterdam UMC, location VUmc6
Leiden University Medical Center5
Eli Lilly and Company3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus188
Diabetes Mellitus, Type 280
Diabetes Mellitus, Type 127
Glucose Metabolism Disorders13
Hypertension13
Cardiovascular Diseases12
Obesity12
Dyslipidemias9
Diabetic Nephropathies8
Insulin Resistance8

Trials

Showing 76 to 100 of 188. Each trial links to its page on Pharma Observatory.

88 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.